secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0001356576-23-000040
Event type: litigation
Sentiment:  negative
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus settles Oxtellar XR patent litigation with Apotex; generic entry allowed Sep 1, 2024
--------------------------------------------------------------------------------

- Settlement resolves patent litigation with Apotex over generic Oxtellar XR (oxcarbazepine ER).
- Apotex granted license to market generic version in U.S. beginning September 1, 2024.
- Supernus retains right to market an authorized generic product itself or through third parties.
- All claims and counter-claims in the patent litigation will be dismissed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657623000040/0001356576-23-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657623000040/supn-20230621.htm
  HTML page:      https://secwatch.observer/filing/0001356576-23-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer